biostudies-literatureDavies BNational Institute for Health Research (NIHR)e061294https://www.ebi.ac.uk/biostudies/studies/S-EPMC10008337biostudies-literatureUnknown13(3)<h4>Introduction</h4>Degenerative cervical myelopathy (DCM) is a common and disabling condition of symptomatic cervical spinal cord compression secondary to degenerative changes in spinal structures leading to a mechanical stress injury of the spinal cord. RECEDE-Myelopathy aims to test the disease-modulating activity of the phosphodiesterase 3/phosphodiesterase 4 inhibitor Ibudilast as an adjuvant to surgical decompression in DCM.<h4>Methods and analysis</h4>RECEDE-Myelopathy is a multicentre, double-blind, randomised, placebo-controlled trial. Participants will be randomised to receive either 60-100 mg Ibudilast or placebo starting within 10 weeks prior to surgery and continuing for 24 weeks after surgery for a maximum of 34 weeks. Adults with DCM, who have a modified Japanese OrthopaediBMJ openTargeting patient recovery priorities in degenerative cervical myelopathy: design and rationale for the RECEDE-Myelopathy trial-study protocol.PMC10008337CS-2015-15-023Choi DAlvarez-Berdugo DSadler IStarkey MHutchinson PJFehlings MGNodale MMowforth ODPapadopoulos MCYordanov SBishop JKotter MRNWhitehead LLamb STrivedi RAKareclas PWilkinson IBSmith LKalsi-Ryan SCarpenter AWilby MBacon MBond SChandran SDavies BfalseTargeting patient recovery priorities in degenerative cervical myelopathy: design and rationale for the RECEDE-Myelopathy trial-study protocol.<h4>Introduction</h4>Degenerative cervical myelopathy (DCM) is a common and disabling condition of symptomatic cervical spinal cord compression secondary to degenerative changes in spinal structures leading to a mechanical stress injury of the spinal cord. RECEDE-Myelopathy aims to test the disease-modulating activity of the phosphodiesterase 3/phosphodiesterase 4 inhibitor Ibudilast as an adjuvant to surgical decompression in DCM.<h4>Methods and analysis</h4>RECEDE-Myelopathy is a multicentre, double-blind, randomised, placebo-controlled trial. Participants will be randomised to receive either 60-100 mg Ibudilast or placebo starting within 10 weeks prior to surgery and continuing for 24 weeks after surgery for a maximum of 34 weeks. Adults with DCM, who have a modified Japanese Orthopaedi2023-01-01T00:00:00Z2023 Mar2025-04-04T11:27:58.672Z2025-04-04T11:27:58.672ZS-EPMC100083373688225910.1136/bmjopen-2022-061294